For instance, PET-PSMA imaging is becoming more commonly used for diagnosis and treatment guidance, novel biomarker-driven systemic treatments (e.g., PARP-inhibitors or immune checkpoint inhibitors) have shown promising results for a subset of patients with prostate cancer, and new radiotherapy modalities (such as photon therapy) are being tested. Here, FOLH1 is linked to prostate carcinoma.